期刊
IMMUNOLOGICAL REVIEWS
卷 297, 期 1, 页码 225-246出版社
WILEY
DOI: 10.1111/imr.12896
关键词
Alzheimer's disease; amyloid beta; microglia; neurodegenerative disease; neuroimmunology; TREM2
类别
资金
- Owens Family Foundation
- National Institutes of Health/National Institute of Neurological Disorders [R01NS106383]
- NIH [T32GM008136]
- Alzheimer's Association [AARG-18-566113]
The amyloid hypothesis has dominated Alzheimer's disease (AD) research for almost 30 years. This hypothesis hinges on the predominant clinical role of the amyloid beta (A beta) peptide in propagating neurofibrillary tangles (NFTs) and eventual cognitive impairment in AD. Recent research in the AD field has identified the brain-resident macrophages, known as microglia, and their receptors as integral regulators of both the initiation and propagation of inflammation, A beta accumulation, neuronal loss, and memory decline in AD. Emerging studies have also begun to reveal critical roles for distinct innate immune pathways in AD pathogenesis, which has led to great interest in harnessing the innate immune response as a therapeutic strategy to treat AD. In this review, we will highlight recent advancements in our understanding of innate immunity and inflammation in AD onset and progression. Additionally, there has been mounting evidence suggesting pivotal contributions of environmental factors and lifestyle choices in AD pathogenesis. Therefore, we will also discuss recent findings, suggesting that many of these AD risk factors influence AD progression via modulation of microglia and immune responses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据